In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)

October 20, 2015 updated by: Carine DE PREZ, Brugmann University Hospital

In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis

The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

5

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Brussels, Belgium, 1020
        • CHU Brugmann

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Archived/residual histopathology slides and paraffin blocks from residual autopsy material from patients who died with amyotrophic lateral sclerosis.

Description

Inclusion Criteria:

  • patients who died with amyotrophic lateral sclerosis, having been autopsied.

Exclusion Criteria:

  • N/A

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Amyotrophic lateral sclerosis (ALS)
Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
Other: in-situ cytokine expression
Control
Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
Other: in-situ cytokine expression

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
in situ cytokine detection: interleukin 18
Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
IHC detection on histopathology sections of paraffin embedded brain tissue.
retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
in situ cytokine detection: interleukin 1
Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
IHC detection on histopathology sections of paraffin embedded brain tissue.
retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
in situ cytokine detection: interleukin 6
Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
IHC detection on histopathology sections of paraffin embedded brain tissue.
retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
in situ cytokine detection:TNF-a
Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
IHC detection on histopathology sections of paraffin embedded brain tissue.
retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Brugmann University Hospital

Investigators

  • Principal Investigator: Hazim Kadhim, MD, PhD, CHU Brugmann

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

October 20, 2015

First Submitted That Met QC Criteria

October 20, 2015

First Posted (Estimate)

October 21, 2015

Study Record Updates

Last Update Posted (Estimate)

October 21, 2015

Last Update Submitted That Met QC Criteria

October 20, 2015

Last Verified

October 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUB-ALS

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe